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BRIEF REPORT

The Management of Keloids: Hands-On Versus
Hands-Off
James Studdiford, MD, Amber Stonehouse, MD, Marc Altshuler, MD, and
Elliot Rinzler, MD
Keloids are benign fibrous growths that appear in scar tissue. The lesions can be severely disfiguring
and early recognition of genetic lesions is crucial. This case report outlines and reviews the important
management strategies for these lesions and the requirement for extensive counseling for the patient
and their family. Many potential medical and surgical interventions exist. Unfortunately, these lesions
tend to recur and overall outcomes remain poor. Given patient susceptibility to disfiguring results, surgical intervention should be used with extreme caution. (J Am Board Fam Med 2008;21:149 –152.)

Case Presentation
A 36-year-old African-American man was seen by
his family physician for management of morbid
obesity and hypertension. Although he was otherwise healthy, he was noted to have marked keloid
formation along his jawline and occiput (Figure 1).
On further questioning he revealed that he had
keloid formation at a very early age; these lesions
formed over areas of bony prominence along his
shoulder, back, chest, occiput, and ear. These facial
lesions remained relatively stable until he began
shaving at age 12. At that time he described the
development of “shaving bumps,” or pseudofolliculitis barbae, which caused ongoing inﬂammation
and added to the keloid formation along his jawline
and neck. There was also signiﬁcant progression in
the bulk of the overall keloid covering his ears.
Surgical excision of the keloid tissue along both
ears was attempted at age 14, but this debulking
procedure exacerbated the problem. This surgical
procedure was not preformed at our institution,
and the operative and pathology reports were un-
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available. Soon after the surgery, keloid formation
recurred to an even greater degree. At age 18, the
patient experienced the formation of new keloids
along his occiput and posterior skull (Figure 2). He
attributed this phenomenon to trauma associated
with participation in high school football competitions. Two years ago, surgical removal of the keloids along his face was again attempted. This time
prophylactic radiation therapy was initiated after
surgery in an attempt to inhibit ﬁbroblast proliferation and diminish the chance of keloid regrowth.
The repeated attempt at debulking was again unsuccessful, and the keloids along his jawline, neck,
and ear returned at greater mass. He also revealed
a strong family history of keloids, with similar
spontaneous formation in several members of his
family. A pedigree (Figure 3) illustrates the prevalence and location of keloids in known relatives.
Given this patient’s strong family history, he and
his family members have since received extensive
counseling regarding the risk of future skin trauma,
avoidance of elective surgeries, early recognition of
infection, and genetic counseling if they are to have
children. With the impressive genogram and nature of inheritance in his family, this patient probably has an autosomal dominant trait that would be
passed on to his children.
From a psychosocial point of view, the patient
admitted to embarrassment and low self-esteem
caused by the disﬁguring nature of his keloids. He
also reported being the subject of repeated ridicule
as a child that left him suffering from depression
and anxiety. After extensive counseling from his
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Figure 1. Large bulky keloid formation along the
jawline encompassing the ear and extending to the
occiput. Seen here after attempted surgical excision
with postoperative radiation therapy.

family doctor he became more comfortable with his
appearance, entered a supportive relationship, and
became gainfully employed.
Figure 3. Familial inheritance pattern of keloids.

Discussion

Figure 2. Multiple keloids along the occiput and
posterior skull as a result of trauma incurred while
wearing a football helmet worn during competitions.
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Keloids develop from a hyperproliferation of dermal ﬁbroblasts and uncontrolled collagen deposition driven by transforming growth factor (TGF)␤.1 These benign ﬁbrous growths represent
exuberant scar tissue that extends beyond the conﬁnes of the initial trauma. These lesions tend to
recur after surgical excision and proliferate in a
pseudotumor manner. Keloids are distinguished
from hypertrophic scars, which adhere to the border of the original trauma and generally retain their
organized conﬁguration. Although the precise
pathogenesis is not fully understood, keloids have a
well-documented familial predilection, most commonly seen in Asian and African-American populations.2 They have been associated genetically
with HLA-B14, HLA-B21, HLA-Bw16, HLABw35, HLA-DR5, HLA-DQw3, and blood group
A.3 In a review by Marneros et al,4 a study of 14
pedigrees with familial keloids, the observed inheritance appeared to be autosomal dominant with
incomplete penetrance. Sporadic appearance of keloids does exist, but distinct characteristics between
genetic and nongenetic keloids have not been determined. Alterations of apoptosis, cell prolifera-
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tion, and overactivation of insulin-like growth factor have all been implicated in the pathogenesis of
keloids.5,6 Sayah et al5 compared the expression of
64 apoptosis-related genes in keloids and normal
scars. Underexpression of 8 of these genes was
found in the ﬁbroblasts derived from keloid tissue.
Keloid ﬁbroblasts fail to undergo physiologically
programmed cell death and therefore continue to
produce connective tissue beyond the period expected for normal scars.
Diagnosis is based on the clinical appearance
and location of the scar tissue. Keloids may occur in
any location, particularly after trauma, but are seen
most commonly on the ears and over bony prominences subject to repeated pressure and friction,
such as the sternum and mandible. Although generally asymptomatic, some keloids may be pruritic
or tender.
Given the generally poor response to treatment
of severe keloids, prevention should be the primary
strategy. (Strength of recommendation level C: expert opinion.)7 All patients at risk for keloid formation should be counseled to avoid unnecessary
trauma (for example, contact football in our patient), body modiﬁcation, and surgical interventions, including tattoos, body piercing, and cosmetic surgery. Any skin infections (such as
folliculitis, pseudofolliculitis, herpes zoster, acne,
or furuncles) in predisposed patients should be
treated aggressively to minimize inﬂammation.8
Young men need to be instructed in proper management of facial hair. Hair should be trimmed
with sharp scissors and cut no shorter than oneeighth of an inch. The family physician should be
aware of other modes of prevention for patients
with a predisposition to keloid formation, such as
the use of semi-occlusive dressings for minor abrasions, splinting after surgical closure of an open
wound to avoid excessive tension on the skin, and
the use of pressure garments consisting of elasticized material over wounds. Table 1 provides a
complete outline of prevention strategies for people predisposed to keloid formation.
For painful or disﬁguring keloids, several treatment options exist for minimizing bulk and recurrence (Table 1). A combination of these therapies is
most effective, but recurrences are common despite
therapy. The earlier keloids are treated, the more
likely it is that they will respond to therapy.
Intralesional steroids are the ﬁrst-line treatment
for most keloids: local anesthesia followed by tri-
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Table 1. Keloid Prevention and Treatment Strategies
Prevention strategies for use in people predisposed to
keloid formation
1. Pressure garment consisting of elasticized material over
wounds.
2. Moist healing by use of dressing impregnated with
ointment.
3. Semi-occlusive dressings for minor abrasions.
4. Splinting after surgical closure of an open wound to
avoid excessive tension on the skin.
5. Injection of triamciniolone acetonide.
6. Silicon gel dressing for 3 months.
Treatment options for patients with keloids*
1. Intralesional steroid injection
2. Surgical excision
a. Scalpel excision
b. Laser excision
c. Electro excision
3. Cryosurgery
4. 5-ﬂurouracil injection
5. Bleomycin injection
6. Interferon ␣-2b injection
*Combination therapy, with one or more of the above treatments, may have greater success rates.

amcinolone 5 to 40 mg/mL injected into the bulk
of the lesion. Injections can be repeated monthly,
but treatment should be discontinued if there is no
response after 4 injections. Skin atrophy and hypopigmentation may occur at higher doses. Seventy
percent of patients respond to intralesional corticosteroid injections with ﬂattening of keloids, although the recurrence rate approaches 50% at 5
years.9
Scalpel, laser, or electro excision can be considered if injection therapy is unsuccessful. However,
these surgical treatments alone result in a recurrence rate of 45% to 100%.10 Therefore, excision
should be used in conjunction with preoperative,
intraoperative, and postoperative steroid injection
and prophylactic radiation therapy to achieve optimum remission rate.
Cryosurgery alone, for keloids ⬍ 6 mm in depth,
has been shown to reduce appearance of keloids in
up to 50% of patients.11,12 The major side effect is
permanent hypopigmentation, which limits use of
cryosurgery in patients with darker skin. Treatment involves a 10- to 30-second freeze-thaw cycle
repeated up to 3 times per treatment session. Therapy may be repeated once per month until response
occurs.
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Several new therapies more speciﬁcally directed
at intervention and prevention of keloids have recently been investigated. Lypka13 found that imiquimod, an immune-modulating medication, effects collagen synthesis in keloids. This study
reported that imiquimod signiﬁcantly suppressed
type I collagen expression in keloid ﬁbroblasts.13 In
another report, Berman et al11 describes the postoperative use of topical imiquimod, which may further reduce the recurrence of keloids. Although
more research needs to be done, these ﬁndings
suggest there may be immune-modulating medications available that could be used in conjunction
with surgery to decrease the recurrence of keloids.
Radiation therapy as the sole modality of treatment must be used with caution given the longterm risks of malignancy. This treatment should be
reserved for recalcitrant keloids that are resistant to
other therapies and are unable to be resected. Adjunctive radiation therapy is highly successful for
reducing keloid recurrence, particularly after surgical excision, with reported control rates of 70%
to 90%.12

Conclusion
For patients with a history of keloids, special care
must be taken after traumatic skin injury. Physicians should be aware that the skin should be closed
with minimal tension and the use of pressure dressings for 3 to 6 months should be considered to
reduce keloid formation.14 Treatment options for
severe familial keloids, as outlined in this case, are
limited and often result in worsening keloid recurrence. The mainstay of therapy should be identiﬁcation of at-risk individuals and extensive counseling regarding prevention. If need be, a combination
of therapies should be used to maximize success
rates. Surgical intervention should be used with
extreme caution given patient susceptibility to disﬁguring outcomes.
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